Trials / Completed
CompletedNCT01752101
Identification of a Plasma Proteomic Signature for Lung Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 475 (actual)
- Sponsor
- Integrated Diagnostics · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Accepted
Summary
The primary objective is to identify a panel of plasma and/or serum proteins that differentiates the absence or presence of lung malignancy in samples obtained from subjects enrolled in this IRB/EC approved study with pulmonary nodules.
Detailed description
Blood samples are obtained from those patients undergoing procedures to determine if a lung nodule is benign or cancerous. The data from the study will not be used to guide or influence the treatment of the patients enrolled in this study. There is no change from the normal standard of care that patients receive.
Conditions
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2012-12-19
- Last updated
- 2015-01-09
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01752101. Inclusion in this directory is not an endorsement.